Navidea Biopharmaceuticals (NAVB) Competitors $0.0002 0.00 (0.00%) As of 10:56 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. VRPX, KRBP, MYMD, TCBP, CAPS, VINC, BON, UPC, SMFL, and HSTOShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Virpax Pharmaceuticals (VRPX), Kiromic BioPharma (KRBP), MyMD Pharmaceuticals (MYMD), TC Biopharm (TCBP), Capstone Therapeutics (CAPS), Vincerx Pharma (VINC), Bon Natural Life (BON), Universe Pharmaceuticals (UPC), Smart for Life (SMFL), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Kiromic BioPharma MyMD Pharmaceuticals TC Biopharm Capstone Therapeutics Vincerx Pharma Bon Natural Life Universe Pharmaceuticals Smart for Life Histogen Navidea Biopharmaceuticals (NYSE:NAVB) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Is NAVB or VRPX more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Do analysts prefer NAVB or VRPX? Virpax Pharmaceuticals has a consensus price target of $75.00, suggesting a potential upside of 19,130.77%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to NAVB or VRPX? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Virpax Pharmaceuticals Neutral Which has higher valuation & earnings, NAVB or VRPX? Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Do institutionals & insiders hold more shares of NAVB or VRPX? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, NAVB or VRPX? Navidea Biopharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. SummaryNavidea Biopharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$20K$14.97M$5.45B$20.43BDividend YieldN/AN/A5.22%3.72%P/E RatioN/AN/A27.2727.80Price / Sales2.4614.27428.4637.78Price / CashN/AN/A26.2118.22Price / BookN/A0.027.924.58Net Income-$15.18M-$15.61M$3.17B$982.91M7 Day PerformanceN/A-9.41%4.33%1.73%1 Month PerformanceN/A-2.91%2.61%4.29%1 Year PerformanceN/A-41.41%34.78%14.25% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-80.0%$20K$8.13K0.0010Gap DownVRPXVirpax Pharmaceuticals1.3423 of 5 stars$0.32+0.3%$75.00+23,634.2%-97.3%$392KN/A0.007Gap DownKRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.13+3.6%N/A-93.5%$308KN/A0.006Gap DownHigh Trading VolumeTCBPTC BiopharmN/A$0.68-55.8%$48.00+6,948.5%-99.5%$279K$4.76M0.0080High Trading VolumeCAPSCapstone TherapeuticsN/A$1.80+7.8%N/AN/A$260K$44.88M0.0038Gap UpHigh Trading VolumeVINCVincerx Pharma2.4448 of 5 stars$0.04-12.0%$40.00+90,809.1%-99.7%$230KN/A0.0060Gap UpBONBon Natural Life1.5239 of 5 stars$1.25-0.8%N/AN/A$210K$23.84M0.00100UPCUniverse PharmaceuticalsN/A$3.75+2.7%N/A-99.8%$161K$23.02M0.00220SMFLSmart for LifeN/A$0.02-62.0%N/AN/A$108K$11.11M0.00110Gap DownHigh Trading VolumeHSTOHistogenN/A$0.01-43.5%N/A-99.9%$43K$19K0.0020Gap Down Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Kiromic BioPharma Competitors MyMD Pharmaceuticals Competitors TC Biopharm Competitors Capstone Therapeutics Competitors Vincerx Pharma Competitors Bon Natural Life Competitors Universe Pharmaceuticals Competitors Smart for Life Competitors Histogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
